Clinical trials
Advanced Cholangiocarcinoma clinical trials
Below are recruiting advanced cholangiocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 56 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07619313RecruitingPhase 1
AB801 with Chemotherapy and Immunotherapy for Bile Duct or Pancreatic Cancer
This study tests a new drug called AB801 combined with standard chemotherapy and immunotherapy for advanced bile duct cancer (cholangiocarcinoma) or pancreatic cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT05823311RecruitingPhase 3
Test lenvatinib and immunotherapy plus chemo for bile duct cancer
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
Hangzhou, ZhejiangAges 18–75 - NCT05532059RecruitingPhase 2
Test lenvatinib, tislelizumab, and chemotherapy for bile duct cancer
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
Hangzhou, ZhejiangAges 18–85 - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06746480RecruitingPhase 2
Study of VG161 for advanced bile duct cancer
This trial tests a new medicine called VG161 for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has stopped responding to or could not be tolerated after at least one prior treatment. It is given by injection into the tumor, and the study wants to see if it can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT04353375RecruitingPhase 2/Phase 3
Study drug for FGFR2-mutated bile duct cancer
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06858735RecruitingPhase 2
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Phase 2 trial evaluating systemic therapy ± liver-directed RT for advanced intrahepatic cholangiocarcinoma, with broad eligibility for patients who have received at least 4 cycles of gem/cis/durvalumab.
Houston, TexasAges 18 years+ - NCT06956716RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for advanced bile duct cancer
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It's for people with advanced bile duct cancer that hasn't been treated yet, to see if it can help their immune system fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT06910722Recruiting
Liver transplant for bile duct cancer after treatment
This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. Before the transplant, you would receive radiation therapy (SIRT) and chemotherapy to shrink the tumor.
Clichy-sous-BoisAges 18–65 - NCT06439485RecruitingPhase 1/Phase 2
Combination drug therapy for advanced bile duct cancer with FGFR2 change
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
Houston, TexasAges 18 years+ - NCT06058663RecruitingPhase 1
Radiation and immunotherapy for advanced bile duct cancer
This trial tests combining a targeted radiation treatment (radioembolization) with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced intrahepatic cholangiocarcinoma that cannot be removed by surgery. It aims to shrink tumors and control cancer spread to lymph nodes or one other organ.
Jacksonville, FloridaAges 18 years+ - NCT05727176RecruitingPhase 2
Futibatinib for advanced bile duct cancer with FGFR2 changes
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT06341764RecruitingPhase 2
Chemo-immunotherapy before surgery for bile duct cancer
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
Naples, ItaliaAges 18 years+ - NCT06438822RecruitingPhase 2
Immunotherapy plus chemo for advanced bile duct cancer
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
Chengdu, SichuanAges 18–75 - NCT07105852RecruitingPhase 2
A new drug combo for advanced bile duct cancer
This trial tests a combination of two drugs, sacituzumab tirumotecan and pucotenlimab, for people with advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread. The goal is to see if this treatment is safe and works well, especially for those with a protein called TROP2 on their cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT06501625RecruitingPhase 1/Phase 2
Targeted therapy plus immunotherapy for IDH1-mutated bile duct cancer
This trial tests a new combination of three drugs (ivosidenib, durvalumab, and gemcitabine/cisplatin) as a first treatment for people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Alamitos, CaliforniaAges 18 years+ - NCT04195503Enrolling by invitation
Liver transplant for stable advanced bile duct cancer
This trial looks at liver transplant for people with advanced intrahepatic cholangiocarcinoma (a bile duct cancer inside the liver) when the cancer is not safely removable and stays controlled. It may help some patients live longer and with better quality of life by replacing the diseased liver—if strict safety and disease-stability requirements are met.
Toronto, OntarioAges 18 years+ - NCT04299581RecruitingPhase 2
Freezing treatment plus immunotherapy for advanced bile-duct cancer
This Phase 2 trial tests whether freezing part of the liver tumor (cryoablation) combined with an immunotherapy drug called anti–PD-1 can shrink advanced bile-duct cancer that can’t be removed by surgery. It may help control the cancer after prior treatments have stopped working.
ShanghaiAges 18 years+ - NCT04954781RecruitingPhase 2
Chemo plus immunotherapy for advanced bile duct liver cancer
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07070700RecruitingPhase 2
Cryoablation with targeted therapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07570849RecruitingPhase 2
Chidamide with chemotherapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of three treatments—chidamide (a new type of cancer drug), chemotherapy, and immunotherapy—for advanced intrahepatic cholangiocarcinoma (a cancer of the bile ducts inside the liver). The goal is to see if this combination can shrink tumors and help patients live longer when used as a first treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05874414RecruitingPhase 1/Phase 2
Combination therapy for advanced KRAS-mutated bile duct cancer
This trial tests a new combination of two drugs, GNS561 and trametinib, for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic change called a KRAS mutation. The goal is to see if this combination can shrink tumors or slow the disease after prior chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT07641036RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Biliary Tract Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target cancer cells in advanced biliary tract cancers—including bile duct and gallbladder cancers. The cells are engineered to recognize and attack cancer cells that have specific markers (HER2 and CEA), and this approach may help patients whose cancer has progressed after standard chemotherapy.
Shenzhen, GuangdongAges 18 years+
Hear when a new Advanced Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced cholangiocarcinoma?
- Yes. Clin2 currently lists 56 recruiting advanced cholangiocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced cholangiocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced cholangiocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.